Biologic therapies for severe asthma include: anti-immunoglobulin (Ig)E (omalizumab); anti-interleukin (IL)-5 (mepolizumab and reslizumab); anti-IL-5 receptor α (IL-5Rα; benralizumab); and anti-IL-4Rα (dupilumab) and anti-thymic stromal lymphopoietin (tezepelumab).12 The gene discussed is IL5; the disease is asthma.